English

ANIKA THERAPEUTICS INC

EDGAR

ANIK Quarterly report (10-Q) · filed 2026-07-29

Annual consolidated revenue for 2025: about USD 112.8M, using the latest reported figures. The previous period, 2024, was about USD 119.9M.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

32.6 million USD

2026 Q2 · USD

Exact inputs and evidence

Revenue: 32610000 USD Source

Operating margin

9.06%

2026 Q2 · %

Exact inputs and evidence

Operating Income: 2954000 USD Source
Revenue: 32610000 USD Source

Operating cash flow

-684 thousand USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -5530000 USD Source
Operating Cash Flow: -4846000 USD Source

Free cash flow

-2.13 million USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -5530000 USD Source
Operating Cash Flow: -4846000 USD Source
Capital Expenditure: 2880000 USD Source
Capital Expenditure: 1431000 USD Source

Cash and cash equivalents: 38.4 million USD 2026-06-30 Source
Exact value

38412000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 13.4 million shares 2026-06-30 Source
Exact value

13383000 shares

Reported share-count change

-7.18% · -1.04 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

14418000 shares · 2025-06-30· Source
13383000 shares · 2026-06-30· Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-07-29.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 8 of 11 periods available· newest 2025-12-31
Operating income: 8 of 11 periods available· newest 2025-12-31
Net income: 8 of 11 periods available· newest 2025-12-31
Operating cash flow: 8 of 11 periods available· newest 2025-12-31
Capital expenditure: 8 of 11 periods available· newest 2025-12-31
Total assets: 7 of 11 periods available· newest 2025-12-31
liabilities: No compatible figures in this window
Current assets: 7 of 11 periods available· newest 2025-12-31
Current liabilities: 7 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 7 of 11 periods available· newest 2025-12-31
long term debt: No compatible figures in this window
Shares outstanding: 7 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
-5.9%

Prior period

USD 119.91 million

2024-01-01 – 2024-12-31
Current period

USD 112.82 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

112819000 − 119907000 = -7088000 USD

119907000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
112819000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · ANIKA THERAPEUTICS INC · 2025-12-31 ANIKA THERAPEUTICS INC (edgar:898437) Year-over-year change in Revenue: -7088000 USD Concept: fundies:Revenue Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T19:43:41Z Snapshot: 2ccd2669b54f707f15eeae262d34af2c267f39233609da5ad464cbe2650617ec Dimensions: Consolidated View: https://fundies.io/companies/edgar/898437?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 112819000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/898437/000117184326001275/anik20251231_10k.htm#1772623 Filing: 000117184326001275 Input fundies:Revenue: 119907000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/898437/000117184326001275/anik20251231_10k.htm#1774266 Filing: 000117184326001275
The citation records this snapshot. The page link may show a newer release later.
Net income
+USD 45.51 million

Prior period

−USD 56.39 million

2024-01-01 – 2024-12-31
Current period

−USD 10.88 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-10880000 − -56385000 = 45505000 USD

-56385000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-10880000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · ANIKA THERAPEUTICS INC · 2025-12-31 ANIKA THERAPEUTICS INC (edgar:898437) Year-over-year change in Net income: 45505000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T19:43:41Z Snapshot: 2ccd2669b54f707f15eeae262d34af2c267f39233609da5ad464cbe2650617ec Dimensions: Consolidated View: https://fundies.io/companies/edgar/898437?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -10880000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/898437/000117184326001275/anik20251231_10k.htm#1193652 Filing: 000117184326001275 Input fundies:NetIncome: -56385000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/898437/000117184326001275/anik20251231_10k.htm#1194444 Filing: 000117184326001275
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+107.1%

Prior period

USD 5.4 million

2024-01-01 – 2024-12-31
Current period

USD 11.19 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

11188000 − 5403000 = 5785000 USD

5403000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
11188000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · ANIKA THERAPEUTICS INC · 2025-12-31 ANIKA THERAPEUTICS INC (edgar:898437) Year-over-year change in Operating cash flow: 5785000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T19:43:41Z Snapshot: 2ccd2669b54f707f15eeae262d34af2c267f39233609da5ad464cbe2650617ec Dimensions: Consolidated View: https://fundies.io/companies/edgar/898437?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: 11188000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/898437/000117184326001275/anik20251231_10k.htm#1243524 Filing: 000117184326001275 Input fundies:OperatingCashFlow: 5403000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/898437/000117184326001275/anik20251231_10k.htm#1244346 Filing: 000117184326001275
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-11.7%

Prior period

USD 7.73 million

2024-01-01 – 2024-12-31
Current period

USD 6.83 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

6826000 − 7734000 = -908000 USD

7734000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
6826000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · ANIKA THERAPEUTICS INC · 2025-12-31 ANIKA THERAPEUTICS INC (edgar:898437) Year-over-year change in Capital expenditure: -908000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T19:43:41Z Snapshot: 2ccd2669b54f707f15eeae262d34af2c267f39233609da5ad464cbe2650617ec Dimensions: Consolidated View: https://fundies.io/companies/edgar/898437?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 6826000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/898437/000117184326001275/anik20251231_10k.htm#1249475 Filing: 000117184326001275 Input fundies:CapitalExpenditure: 7734000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/898437/000117184326001275/anik20251231_10k.htm#1250175 Filing: 000117184326001275
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2025-01-01 – 2025-12-31

Revenue USD 112.82 million 100% of revenue
Cost of revenue USD 49.01 million 43% of revenue
Operating expenses USD 74.86 million 66% of revenue
Operating income −USD 11.05 million −9.8% of revenue
Tax, interest and other Derived −USD 171,000 −0.2% of revenue
Net income −USD 10.88 million −9.6% of revenue

Cash

Operating cash flow USD 11.19 million 9.9% of revenue
Capital expenditure USD 6.83 million 6.1% of revenue
Free cash flow Derived USD 4.36 million 3.9% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2018 18%79%
2019 24%70%
2020 Operating loss: operating costs were 122% of revenue.
2021 Net income was higher than operating income, so the split is not drawn.
2022 Net loss: net income was −13% of revenue.
2023 Net loss: net income was −68% of revenue.
2024 Operating loss: operating costs were 104% of revenue.
2025 Operating loss: operating costs were 110% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2018 2018-01-01 – 2018-12-31	105555000	83806000 Derived	21749000	3027000 Derived	18722000	30262000 Derived	Source 2018-01-01 – 2018-12-31: 105555000 USD Inspect Revenue Open source 2018-01-01 – 2018-12-31: 21749000 USD Inspect Operating Income Open source 2018-01-01 – 2018-12-31: 18722000 USD Inspect Net Income Open source 2018-01-01 – 2018-12-31: 34918000 USD Inspect Operating Cash Flow Open source 2018-01-01 – 2018-12-31: 4656000 USD Inspect Capital Expenditure Open source
2019 2019-01-01 – 2019-12-31	114610000	80362000 Derived	34248000	7055000 Derived	27193000	34178000 Derived	Source 2019-01-01 – 2019-12-31: 114610000 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: 34248000 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: 27193000 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: 37005000 USD Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: 2827000 USD Inspect Capital Expenditure Open source
2020 2020-01-01 – 2020-12-31	130457000	158779000 Derived	-28322000	-4340000 Derived	-23982000	11437000 Derived	Source 2020-01-01 – 2020-12-31: 130457000 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -28322000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -23982000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: 13065000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 1628000 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	147794000	145179000 Derived	2615000	-1519000 Derived	4134000	3254000 Derived	Source 2021-01-01 – 2021-12-31: 147794000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: 2615000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: 4134000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: 8397000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 5143000 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	113827000	110157000 Derived	3670000	18529000 Derived	-14859000	-3077000 Derived	Source 2022-01-01 – 2022-12-31: 113827000 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: 3670000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -14859000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: 4409000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 7486000 USD Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	120792000	119948000 Derived	844000	83511000 Derived	-82667000	-7215000 Derived	Source 2023-01-01 – 2023-12-31: 120792000 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: 844000 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -82667000 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -1788000 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 5427000 USD Inspect Capital Expenditure Open source
2024 2024-01-01 – 2024-12-31	119907000	125008000 Derived	-5101000	51284000 Derived	-56385000	-2331000 Derived	Source 2024-01-01 – 2024-12-31: 119907000 USD Inspect Revenue Open source 2024-01-01 – 2024-12-31: -5101000 USD Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -56385000 USD Inspect Net Income Open source 2024-01-01 – 2024-12-31: 5403000 USD Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 7734000 USD Inspect Capital Expenditure Open source
2025 2025-01-01 – 2025-12-31	112819000	123870000 Derived	-11051000	-171000 Derived	-10880000	4362000 Derived	Source 2025-01-01 – 2025-12-31: 112819000 USD Inspect Revenue Open source 2025-01-01 – 2025-12-31: -11051000 USD Inspect Operating Income Open source 2025-01-01 – 2025-12-31: -10880000 USD Inspect Net Income Open source 2025-01-01 – 2025-12-31: 11188000 USD Inspect Operating Cash Flow Open source 2025-01-01 – 2025-12-31: 6826000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 112.8M 2025

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20182018-12-31	Revenue	105555000	Revenue: 105555000 Open source
20192019-12-31	Revenue	114610000	Revenue: 114610000 Open source
20202020-12-31	Revenue	130457000	Revenue: 130457000 Open source
20212021-12-31	Revenue	147794000	Revenue: 147794000 Open source
20222022-12-31	Revenue	113827000	Revenue: 113827000 Open source
20232023-12-31	Revenue	120792000	Revenue: 120792000 Open source
20242024-12-31	Revenue	119907000	Revenue: 119907000 Open source
20252025-12-31	Revenue	112819000	Revenue: 112819000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-5.9% 2025

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20182018-12-31	Year over year	No prior comparable period	Revenue: 105555000 Open source
20192019-12-31	Year over year	8.6%	Revenue: 114610000 Open source Revenue: 105555000 Open source
20202020-12-31	Year over year	13.8%	Revenue: 130457000 Open source Revenue: 114610000 Open source
20212021-12-31	Year over year	13.3%	Revenue: 147794000 Open source Revenue: 130457000 Open source
20222022-12-31	Year over year	-23%	Revenue: 113827000 Open source Revenue: 147794000 Open source
20232023-12-31	Year over year	6.1%	Revenue: 120792000 Open source Revenue: 113827000 Open source
20242024-12-31	Year over year	-0.7%	Revenue: 119907000 Open source Revenue: 120792000 Open source
20252025-12-31	Year over year	-5.9%	Revenue: 112819000 Open source Revenue: 119907000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -9.8% 2025

Net margin -9.6% 2025

Free cash flow margin 3.9% 2025

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20182018-12-31	Operating margin	20.6%	Operating Income: 21749000 Open source Revenue: 105555000 Open source
20192019-12-31	Operating margin	29.9%	Operating Income: 34248000 Open source Revenue: 114610000 Open source
20202020-12-31	Operating margin	-21.7%	Operating Income: -28322000 Open source Revenue: 130457000 Open source
20212021-12-31	Operating margin	1.8%	Operating Income: 2615000 Open source Revenue: 147794000 Open source
20222022-12-31	Operating margin	3.2%	Operating Income: 3670000 Open source Revenue: 113827000 Open source
20232023-12-31	Operating margin	0.7%	Operating Income: 844000 Open source Revenue: 120792000 Open source
20242024-12-31	Operating margin	-4.3%	Operating Income: -5101000 Open source Revenue: 119907000 Open source
20252025-12-31	Operating margin	-9.8%	Operating Income: -11051000 Open source Revenue: 112819000 Open source
20182018-12-31	Net margin	17.7%	Net Income: 18722000 Open source Revenue: 105555000 Open source
20192019-12-31	Net margin	23.7%	Net Income: 27193000 Open source Revenue: 114610000 Open source
20202020-12-31	Net margin	-18.4%	Net Income: -23982000 Open source Revenue: 130457000 Open source
20212021-12-31	Net margin	2.8%	Net Income: 4134000 Open source Revenue: 147794000 Open source
20222022-12-31	Net margin	-13.1%	Net Income: -14859000 Open source Revenue: 113827000 Open source
20232023-12-31	Net margin	-68.4%	Net Income: -82667000 Open source Revenue: 120792000 Open source
20242024-12-31	Net margin	-47%	Net Income: -56385000 Open source Revenue: 119907000 Open source
20252025-12-31	Net margin	-9.6%	Net Income: -10880000 Open source Revenue: 112819000 Open source
20182018-12-31	Free cash flow margin	28.7%	Revenue: 105555000 Open source Operating Cash Flow: 34918000 Open source Capital Expenditure: 4656000 Open source
20192019-12-31	Free cash flow margin	29.8%	Revenue: 114610000 Open source Operating Cash Flow: 37005000 Open source Capital Expenditure: 2827000 Open source
20202020-12-31	Free cash flow margin	8.8%	Revenue: 130457000 Open source Operating Cash Flow: 13065000 Open source Capital Expenditure: 1628000 Open source
20212021-12-31	Free cash flow margin	2.2%	Revenue: 147794000 Open source Operating Cash Flow: 8397000 Open source Capital Expenditure: 5143000 Open source
20222022-12-31	Free cash flow margin	-2.7%	Revenue: 113827000 Open source Operating Cash Flow: 4409000 Open source Capital Expenditure: 7486000 Open source
20232023-12-31	Free cash flow margin	-6%	Revenue: 120792000 Open source Operating Cash Flow: -1788000 Open source Capital Expenditure: 5427000 Open source
20242024-12-31	Free cash flow margin	-1.9%	Revenue: 119907000 Open source Operating Cash Flow: 5403000 Open source Capital Expenditure: 7734000 Open source
20252025-12-31	Free cash flow margin	3.9%	Revenue: 112819000 Open source Operating Cash Flow: 11188000 Open source Capital Expenditure: 6826000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD 11.2M 2025

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20182018-12-31	Operating cash flow	34918000	Operating Cash Flow: 34918000 Open source
20192019-12-31	Operating cash flow	37005000	Operating Cash Flow: 37005000 Open source
20202020-12-31	Operating cash flow	13065000	Operating Cash Flow: 13065000 Open source
20212021-12-31	Operating cash flow	8397000	Operating Cash Flow: 8397000 Open source
20222022-12-31	Operating cash flow	4409000	Operating Cash Flow: 4409000 Open source
20232023-12-31	Operating cash flow	-1788000	Operating Cash Flow: -1788000 Open source
20242024-12-31	Operating cash flow	5403000	Operating Cash Flow: 5403000 Open source
20252025-12-31	Operating cash flow	11188000	Operating Cash Flow: 11188000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD 4.4M 2025

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20182018-12-31	Free cash flow	30262000	Operating Cash Flow: 34918000 Open source Capital Expenditure: 4656000 Open source
20192019-12-31	Free cash flow	34178000	Operating Cash Flow: 37005000 Open source Capital Expenditure: 2827000 Open source
20202020-12-31	Free cash flow	11437000	Operating Cash Flow: 13065000 Open source Capital Expenditure: 1628000 Open source
20212021-12-31	Free cash flow	3254000	Operating Cash Flow: 8397000 Open source Capital Expenditure: 5143000 Open source
20222022-12-31	Free cash flow	-3077000	Operating Cash Flow: 4409000 Open source Capital Expenditure: 7486000 Open source
20232023-12-31	Free cash flow	-7215000	Operating Cash Flow: -1788000 Open source Capital Expenditure: 5427000 Open source
20242024-12-31	Free cash flow	-2331000	Operating Cash Flow: 5403000 Open source Capital Expenditure: 7734000 Open source
20252025-12-31	Free cash flow	4362000	Operating Cash Flow: 11188000 Open source Capital Expenditure: 6826000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

Not enough comparable data to show this history.

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
2018-12-31	Liabilities / assets	Not reported	No source recorded
2019-12-31	Liabilities / assets	Not reported	Total Assets: 330710000 Open source
2020-12-31	Liabilities / assets	Not reported	Total Assets: 365605000 Open source
2021-12-31	Liabilities / assets	Not reported	Total Assets: 347535000 Open source
2022-12-31	Liabilities / assets	Not reported	Total Assets: 349128000 Open source
2023-12-31	Liabilities / assets	Not reported	Total Assets: 270632000 Open source
2024-12-31	Liabilities / assets	Not reported	Total Assets: 202740000 Open source
2025-12-31	Liabilities / assets	Not reported	Total Assets: 190270000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

4.72× 2025

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
2018-12-31	Current assets / current liabilities	Not reported	No source recorded
20192019-12-31	Current assets / current liabilities	14.39×	Current Assets: 234306000 Open source Current Liabilities: 16277000 Open source
20202020-12-31	Current assets / current liabilities	4.81×	Current Assets: 177383000 Open source Current Liabilities: 36867000 Open source
20212021-12-31	Current assets / current liabilities	5.66×	Current Assets: 168528000 Open source Current Liabilities: 29795000 Open source
20222022-12-31	Current assets / current liabilities	6.07×	Current Assets: 169547000 Open source Current Liabilities: 27914000 Open source
20232023-12-31	Current assets / current liabilities	5.26×	Current Assets: 163309000 Open source Current Liabilities: 31059000 Open source
20242024-12-31	Current assets / current liabilities	4.88×	Current Assets: 113652000 Open source Current Liabilities: 23306000 Open source
20252025-12-31	Current assets / current liabilities	4.72×	Current Assets: 103358000 Open source Current Liabilities: 21908000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2018 2018-01-01 – 2018-12-31	USD 18.72 million Exact value Exact value: 18722000 USD 2018-01-01 – 2018-12-31: 18722000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ANIKA THERAPEUTICS INC · 2018-12-31 ANIKA THERAPEUTICS INC (edgar:898437) Net Income: 18722000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T19:43:41Z Snapshot: 2ccd2669b54f707f15eeae262d34af2c267f39233609da5ad464cbe2650617ec Dimensions: Consolidated View: https://fundies.io/companies/edgar/898437/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: 18722000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/898437/000117184321002766/anik20201231_10ka.htm#880689 Filing: 000117184321002766 The citation records this snapshot. The page link may show a newer release later.	USD 34.92 million Exact value Exact value: 34918000 USD 2018-01-01 – 2018-12-31: 34918000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ANIKA THERAPEUTICS INC · 2018-12-31 ANIKA THERAPEUTICS INC (edgar:898437) Operating Cash Flow: 34918000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T19:43:41Z Snapshot: 2ccd2669b54f707f15eeae262d34af2c267f39233609da5ad464cbe2650617ec Dimensions: Consolidated View: https://fundies.io/companies/edgar/898437/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 34918000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/898437/000117184321002766/anik20201231_10ka.htm#941048 Filing: 000117184321002766 The citation records this snapshot. The page link may show a newer release later.	USD 4.66 million Exact value Exact value: 4656000 USD 2018-01-01 – 2018-12-31: 4656000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ANIKA THERAPEUTICS INC · 2018-12-31 ANIKA THERAPEUTICS INC (edgar:898437) Capital Expenditure: 4656000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T19:43:41Z Snapshot: 2ccd2669b54f707f15eeae262d34af2c267f39233609da5ad464cbe2650617ec Dimensions: Consolidated View: https://fundies.io/companies/edgar/898437/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 4656000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/898437/000117184321002766/anik20201231_10ka.htm#953884 Filing: 000117184321002766 The citation records this snapshot. The page link may show a newer release later.	USD 30.26 million Calculation and evidence 34918000 − 4656000 USD Exact free cash flow: 30262000 USD 2018-01-01 – 2018-12-31: 34918000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 4656000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ANIKA THERAPEUTICS INC · 2018-12-31 ANIKA THERAPEUTICS INC (edgar:898437) Free cash flow: 30262000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T19:43:41Z Snapshot: 2ccd2669b54f707f15eeae262d34af2c267f39233609da5ad464cbe2650617ec Dimensions: Consolidated View: https://fundies.io/companies/edgar/898437?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 34918000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/898437/000117184321002766/anik20201231_10ka.htm#941048 Filing: 000117184321002766 Input fundies:CapitalExpenditure: 4656000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/898437/000117184321002766/anik20201231_10ka.htm#953884 Filing: 000117184321002766 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	USD 27.19 million Exact value Exact value: 27193000 USD 2019-01-01 – 2019-12-31: 27193000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ANIKA THERAPEUTICS INC · 2019-12-31 ANIKA THERAPEUTICS INC (edgar:898437) Net Income: 27193000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T19:43:41Z Snapshot: 2ccd2669b54f707f15eeae262d34af2c267f39233609da5ad464cbe2650617ec Dimensions: Consolidated View: https://fundies.io/companies/edgar/898437/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: 27193000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/898437/000117184322001790/anik20211231_10k.htm#1058860 Filing: 000117184322001790 The citation records this snapshot. The page link may show a newer release later.	USD 37.01 million Exact value Exact value: 37005000 USD 2019-01-01 – 2019-12-31: 37005000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ANIKA THERAPEUTICS INC · 2019-12-31 ANIKA THERAPEUTICS INC (edgar:898437) Operating Cash Flow: 37005000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T19:43:41Z Snapshot: 2ccd2669b54f707f15eeae262d34af2c267f39233609da5ad464cbe2650617ec Dimensions: Consolidated View: https://fundies.io/companies/edgar/898437/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 37005000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/898437/000117184322001790/anik20211231_10k.htm#1110797 Filing: 000117184322001790 The citation records this snapshot. The page link may show a newer release later.	USD 2.83 million Exact value Exact value: 2827000 USD 2019-01-01 – 2019-12-31: 2827000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ANIKA THERAPEUTICS INC · 2019-12-31 ANIKA THERAPEUTICS INC (edgar:898437) Capital Expenditure: 2827000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T19:43:41Z Snapshot: 2ccd2669b54f707f15eeae262d34af2c267f39233609da5ad464cbe2650617ec Dimensions: Consolidated View: https://fundies.io/companies/edgar/898437/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2827000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/898437/000117184322001790/anik20211231_10k.htm#1121830 Filing: 000117184322001790 The citation records this snapshot. The page link may show a newer release later.	USD 34.18 million Calculation and evidence 37005000 − 2827000 USD Exact free cash flow: 34178000 USD 2019-01-01 – 2019-12-31: 37005000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 2827000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ANIKA THERAPEUTICS INC · 2019-12-31 ANIKA THERAPEUTICS INC (edgar:898437) Free cash flow: 34178000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T19:43:41Z Snapshot: 2ccd2669b54f707f15eeae262d34af2c267f39233609da5ad464cbe2650617ec Dimensions: Consolidated View: https://fundies.io/companies/edgar/898437?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 37005000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/898437/000117184322001790/anik20211231_10k.htm#1110797 Filing: 000117184322001790 Input fundies:CapitalExpenditure: 2827000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/898437/000117184322001790/anik20211231_10k.htm#1121830 Filing: 000117184322001790 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 23.98 million Exact value Exact value: -23982000 USD 2020-01-01 – 2020-12-31: -23982000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ANIKA THERAPEUTICS INC · 2020-12-31 ANIKA THERAPEUTICS INC (edgar:898437) Net Income: -23982000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T19:43:41Z Snapshot: 2ccd2669b54f707f15eeae262d34af2c267f39233609da5ad464cbe2650617ec Dimensions: Consolidated View: https://fundies.io/companies/edgar/898437/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -23982000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/898437/000117184323001729/anik20221231_10k.htm#1104238 Filing: 000117184323001729 The citation records this snapshot. The page link may show a newer release later.	USD 13.07 million Exact value Exact value: 13065000 USD 2020-01-01 – 2020-12-31: 13065000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ANIKA THERAPEUTICS INC · 2020-12-31 ANIKA THERAPEUTICS INC (edgar:898437) Operating Cash Flow: 13065000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T19:43:41Z Snapshot: 2ccd2669b54f707f15eeae262d34af2c267f39233609da5ad464cbe2650617ec Dimensions: Consolidated View: https://fundies.io/companies/edgar/898437/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 13065000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/898437/000117184323001729/anik20221231_10k.htm#1160798 Filing: 000117184323001729 The citation records this snapshot. The page link may show a newer release later.	USD 1.63 million Exact value Exact value: 1628000 USD 2020-01-01 – 2020-12-31: 1628000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ANIKA THERAPEUTICS INC · 2020-12-31 ANIKA THERAPEUTICS INC (edgar:898437) Capital Expenditure: 1628000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T19:43:41Z Snapshot: 2ccd2669b54f707f15eeae262d34af2c267f39233609da5ad464cbe2650617ec Dimensions: Consolidated View: https://fundies.io/companies/edgar/898437/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1628000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/898437/000117184323001729/anik20221231_10k.htm#1173106 Filing: 000117184323001729 The citation records this snapshot. The page link may show a newer release later.	USD 11.44 million Calculation and evidence 13065000 − 1628000 USD Exact free cash flow: 11437000 USD 2020-01-01 – 2020-12-31: 13065000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 1628000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ANIKA THERAPEUTICS INC · 2020-12-31 ANIKA THERAPEUTICS INC (edgar:898437) Free cash flow: 11437000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T19:43:41Z Snapshot: 2ccd2669b54f707f15eeae262d34af2c267f39233609da5ad464cbe2650617ec Dimensions: Consolidated View: https://fundies.io/companies/edgar/898437?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 13065000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/898437/000117184323001729/anik20221231_10k.htm#1160798 Filing: 000117184323001729 Input fundies:CapitalExpenditure: 1628000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/898437/000117184323001729/anik20221231_10k.htm#1173106 Filing: 000117184323001729 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	USD 4.13 million Exact value Exact value: 4134000 USD 2021-01-01 – 2021-12-31: 4134000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ANIKA THERAPEUTICS INC · 2021-12-31 ANIKA THERAPEUTICS INC (edgar:898437) Net Income: 4134000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T19:43:41Z Snapshot: 2ccd2669b54f707f15eeae262d34af2c267f39233609da5ad464cbe2650617ec Dimensions: Consolidated View: https://fundies.io/companies/edgar/898437/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: 4134000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/898437/000117184324001380/anik20231231_10k.htm#1134784 Filing: 000117184324001380 The citation records this snapshot. The page link may show a newer release later.	USD 8.4 million Exact value Exact value: 8397000 USD 2021-01-01 – 2021-12-31: 8397000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ANIKA THERAPEUTICS INC · 2021-12-31 ANIKA THERAPEUTICS INC (edgar:898437) Operating Cash Flow: 8397000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T19:43:41Z Snapshot: 2ccd2669b54f707f15eeae262d34af2c267f39233609da5ad464cbe2650617ec Dimensions: Consolidated View: https://fundies.io/companies/edgar/898437/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 8397000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/898437/000117184324001380/anik20231231_10k.htm#1193479 Filing: 000117184324001380 The citation records this snapshot. The page link may show a newer release later.	USD 5.14 million Exact value Exact value: 5143000 USD 2021-01-01 – 2021-12-31: 5143000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ANIKA THERAPEUTICS INC · 2021-12-31 ANIKA THERAPEUTICS INC (edgar:898437) Capital Expenditure: 5143000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T19:43:41Z Snapshot: 2ccd2669b54f707f15eeae262d34af2c267f39233609da5ad464cbe2650617ec Dimensions: Consolidated View: https://fundies.io/companies/edgar/898437/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 5143000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/898437/000117184324001380/anik20231231_10k.htm#1204920 Filing: 000117184324001380 The citation records this snapshot. The page link may show a newer release later.	USD 3.25 million Calculation and evidence 8397000 − 5143000 USD Exact free cash flow: 3254000 USD 2021-01-01 – 2021-12-31: 8397000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 5143000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ANIKA THERAPEUTICS INC · 2021-12-31 ANIKA THERAPEUTICS INC (edgar:898437) Free cash flow: 3254000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T19:43:41Z Snapshot: 2ccd2669b54f707f15eeae262d34af2c267f39233609da5ad464cbe2650617ec Dimensions: Consolidated View: https://fundies.io/companies/edgar/898437?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 8397000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/898437/000117184324001380/anik20231231_10k.htm#1193479 Filing: 000117184324001380 Input fundies:CapitalExpenditure: 5143000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/898437/000117184324001380/anik20231231_10k.htm#1204920 Filing: 000117184324001380 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 14.86 million Exact value Exact value: -14859000 USD 2022-01-01 – 2022-12-31: -14859000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ANIKA THERAPEUTICS INC · 2022-12-31 ANIKA THERAPEUTICS INC (edgar:898437) Net Income: -14859000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T19:43:41Z Snapshot: 2ccd2669b54f707f15eeae262d34af2c267f39233609da5ad464cbe2650617ec Dimensions: Consolidated View: https://fundies.io/companies/edgar/898437/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -14859000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/898437/000117184325001486/anik20241231_10k.htm#1140761 Filing: 000117184325001486 The citation records this snapshot. The page link may show a newer release later.	USD 4.41 million Exact value Exact value: 4409000 USD 2022-01-01 – 2022-12-31: 4409000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ANIKA THERAPEUTICS INC · 2022-12-31 ANIKA THERAPEUTICS INC (edgar:898437) Operating Cash Flow: 4409000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T19:43:41Z Snapshot: 2ccd2669b54f707f15eeae262d34af2c267f39233609da5ad464cbe2650617ec Dimensions: Consolidated View: https://fundies.io/companies/edgar/898437/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 4409000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/898437/000117184325001486/anik20241231_10k.htm#1188000 Filing: 000117184325001486 The citation records this snapshot. The page link may show a newer release later.	USD 7.49 million Exact value Exact value: 7486000 USD 2022-01-01 – 2022-12-31: 7486000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ANIKA THERAPEUTICS INC · 2022-12-31 ANIKA THERAPEUTICS INC (edgar:898437) Capital Expenditure: 7486000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T19:43:41Z Snapshot: 2ccd2669b54f707f15eeae262d34af2c267f39233609da5ad464cbe2650617ec Dimensions: Consolidated View: https://fundies.io/companies/edgar/898437/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 7486000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/898437/000117184325001486/anik20241231_10k.htm#1194068 Filing: 000117184325001486 The citation records this snapshot. The page link may show a newer release later.	−USD 3.08 million Calculation and evidence 4409000 − 7486000 USD Exact free cash flow: -3077000 USD 2022-01-01 – 2022-12-31: 4409000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 7486000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ANIKA THERAPEUTICS INC · 2022-12-31 ANIKA THERAPEUTICS INC (edgar:898437) Free cash flow: -3077000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T19:43:41Z Snapshot: 2ccd2669b54f707f15eeae262d34af2c267f39233609da5ad464cbe2650617ec Dimensions: Consolidated View: https://fundies.io/companies/edgar/898437?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 4409000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/898437/000117184325001486/anik20241231_10k.htm#1188000 Filing: 000117184325001486 Input fundies:CapitalExpenditure: 7486000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/898437/000117184325001486/anik20241231_10k.htm#1194068 Filing: 000117184325001486 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 82.67 million Exact value Exact value: -82667000 USD 2023-01-01 – 2023-12-31: -82667000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ANIKA THERAPEUTICS INC · 2023-12-31 ANIKA THERAPEUTICS INC (edgar:898437) Net Income: -82667000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T19:43:41Z Snapshot: 2ccd2669b54f707f15eeae262d34af2c267f39233609da5ad464cbe2650617ec Dimensions: Consolidated View: https://fundies.io/companies/edgar/898437/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -82667000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/898437/000117184326001275/anik20251231_10k.htm#1195236 Filing: 000117184326001275 The citation records this snapshot. The page link may show a newer release later.	−USD 1.79 million Exact value Exact value: -1788000 USD 2023-01-01 – 2023-12-31: -1788000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ANIKA THERAPEUTICS INC · 2023-12-31 ANIKA THERAPEUTICS INC (edgar:898437) Operating Cash Flow: -1788000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T19:43:41Z Snapshot: 2ccd2669b54f707f15eeae262d34af2c267f39233609da5ad464cbe2650617ec Dimensions: Consolidated View: https://fundies.io/companies/edgar/898437/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -1788000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/898437/000117184326001275/anik20251231_10k.htm#1245168 Filing: 000117184326001275 The citation records this snapshot. The page link may show a newer release later.	USD 5.43 million Exact value Exact value: 5427000 USD 2023-01-01 – 2023-12-31: 5427000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ANIKA THERAPEUTICS INC · 2023-12-31 ANIKA THERAPEUTICS INC (edgar:898437) Capital Expenditure: 5427000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T19:43:41Z Snapshot: 2ccd2669b54f707f15eeae262d34af2c267f39233609da5ad464cbe2650617ec Dimensions: Consolidated View: https://fundies.io/companies/edgar/898437/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 5427000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/898437/000117184326001275/anik20251231_10k.htm#1250875 Filing: 000117184326001275 The citation records this snapshot. The page link may show a newer release later.	−USD 7.22 million Calculation and evidence -1788000 − 5427000 USD Exact free cash flow: -7215000 USD 2023-01-01 – 2023-12-31: -1788000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 5427000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ANIKA THERAPEUTICS INC · 2023-12-31 ANIKA THERAPEUTICS INC (edgar:898437) Free cash flow: -7215000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T19:43:41Z Snapshot: 2ccd2669b54f707f15eeae262d34af2c267f39233609da5ad464cbe2650617ec Dimensions: Consolidated View: https://fundies.io/companies/edgar/898437?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -1788000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/898437/000117184326001275/anik20251231_10k.htm#1245168 Filing: 000117184326001275 Input fundies:CapitalExpenditure: 5427000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/898437/000117184326001275/anik20251231_10k.htm#1250875 Filing: 000117184326001275 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 56.39 million Exact value Exact value: -56385000 USD 2024-01-01 – 2024-12-31: -56385000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ANIKA THERAPEUTICS INC · 2024-12-31 ANIKA THERAPEUTICS INC (edgar:898437) Net Income: -56385000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T19:43:41Z Snapshot: 2ccd2669b54f707f15eeae262d34af2c267f39233609da5ad464cbe2650617ec Dimensions: Consolidated View: https://fundies.io/companies/edgar/898437/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -56385000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/898437/000117184326001275/anik20251231_10k.htm#1194444 Filing: 000117184326001275 The citation records this snapshot. The page link may show a newer release later.	USD 5.4 million Exact value Exact value: 5403000 USD 2024-01-01 – 2024-12-31: 5403000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ANIKA THERAPEUTICS INC · 2024-12-31 ANIKA THERAPEUTICS INC (edgar:898437) Operating Cash Flow: 5403000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T19:43:41Z Snapshot: 2ccd2669b54f707f15eeae262d34af2c267f39233609da5ad464cbe2650617ec Dimensions: Consolidated View: https://fundies.io/companies/edgar/898437/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 5403000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/898437/000117184326001275/anik20251231_10k.htm#1244346 Filing: 000117184326001275 The citation records this snapshot. The page link may show a newer release later.	USD 7.73 million Exact value Exact value: 7734000 USD 2024-01-01 – 2024-12-31: 7734000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ANIKA THERAPEUTICS INC · 2024-12-31 ANIKA THERAPEUTICS INC (edgar:898437) Capital Expenditure: 7734000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T19:43:41Z Snapshot: 2ccd2669b54f707f15eeae262d34af2c267f39233609da5ad464cbe2650617ec Dimensions: Consolidated View: https://fundies.io/companies/edgar/898437/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 7734000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/898437/000117184326001275/anik20251231_10k.htm#1250175 Filing: 000117184326001275 The citation records this snapshot. The page link may show a newer release later.	−USD 2.33 million Calculation and evidence 5403000 − 7734000 USD Exact free cash flow: -2331000 USD 2024-01-01 – 2024-12-31: 5403000 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 7734000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ANIKA THERAPEUTICS INC · 2024-12-31 ANIKA THERAPEUTICS INC (edgar:898437) Free cash flow: -2331000 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T19:43:41Z Snapshot: 2ccd2669b54f707f15eeae262d34af2c267f39233609da5ad464cbe2650617ec Dimensions: Consolidated View: https://fundies.io/companies/edgar/898437?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 5403000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/898437/000117184326001275/anik20251231_10k.htm#1244346 Filing: 000117184326001275 Input fundies:CapitalExpenditure: 7734000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/898437/000117184326001275/anik20251231_10k.htm#1250175 Filing: 000117184326001275 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	−USD 10.88 million Exact value Exact value: -10880000 USD 2025-01-01 – 2025-12-31: -10880000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ANIKA THERAPEUTICS INC · 2025-12-31 ANIKA THERAPEUTICS INC (edgar:898437) Net Income: -10880000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T19:43:41Z Snapshot: 2ccd2669b54f707f15eeae262d34af2c267f39233609da5ad464cbe2650617ec Dimensions: Consolidated View: https://fundies.io/companies/edgar/898437/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -10880000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/898437/000117184326001275/anik20251231_10k.htm#1193652 Filing: 000117184326001275 The citation records this snapshot. The page link may show a newer release later.	USD 11.19 million Exact value Exact value: 11188000 USD 2025-01-01 – 2025-12-31: 11188000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ANIKA THERAPEUTICS INC · 2025-12-31 ANIKA THERAPEUTICS INC (edgar:898437) Operating Cash Flow: 11188000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T19:43:41Z Snapshot: 2ccd2669b54f707f15eeae262d34af2c267f39233609da5ad464cbe2650617ec Dimensions: Consolidated View: https://fundies.io/companies/edgar/898437/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 11188000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/898437/000117184326001275/anik20251231_10k.htm#1243524 Filing: 000117184326001275 The citation records this snapshot. The page link may show a newer release later.	USD 6.83 million Exact value Exact value: 6826000 USD 2025-01-01 – 2025-12-31: 6826000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ANIKA THERAPEUTICS INC · 2025-12-31 ANIKA THERAPEUTICS INC (edgar:898437) Capital Expenditure: 6826000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T19:43:41Z Snapshot: 2ccd2669b54f707f15eeae262d34af2c267f39233609da5ad464cbe2650617ec Dimensions: Consolidated View: https://fundies.io/companies/edgar/898437/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 6826000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/898437/000117184326001275/anik20251231_10k.htm#1249475 Filing: 000117184326001275 The citation records this snapshot. The page link may show a newer release later.	USD 4.36 million Calculation and evidence 11188000 − 6826000 USD Exact free cash flow: 4362000 USD 2025-01-01 – 2025-12-31: 11188000 USD · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 6826000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ANIKA THERAPEUTICS INC · 2025-12-31 ANIKA THERAPEUTICS INC (edgar:898437) Free cash flow: 4362000 USD Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T19:43:41Z Snapshot: 2ccd2669b54f707f15eeae262d34af2c267f39233609da5ad464cbe2650617ec Dimensions: Consolidated View: https://fundies.io/companies/edgar/898437?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 11188000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/898437/000117184326001275/anik20251231_10k.htm#1243524 Filing: 000117184326001275 Input fundies:CapitalExpenditure: 6826000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/898437/000117184326001275/anik20251231_10k.htm#1249475 Filing: 000117184326001275 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

212 filings · 5,826 latest values · 5,826 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0000898437, 898437, ANIK, anik, edgar:898437

Also known as ANIKA RESEARCH INC, ANIKA THERAPEUTICS INC, Anika Therapeutics, Inc.

ANIKA THERAPEUTICS INC

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2025 2025-01-01 – 2025-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation